Premium
Long noncoding RNA BHLHE40‐AS1 promotes early breast cancer progression through modulating IL‐6/STAT3 signaling
Author(s) -
DeVaux Rebecca S.,
Ropri Ali S.,
Grimm Sandra L.,
Hall Peter A.,
Herrera Emilio O.,
Chittur Sridar V.,
Smith William P.,
Coarfa Cristian,
Behbod Fariba,
Herschkowitz Jason I.
Publication year - 2020
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29621
Subject(s) - ductal carcinoma , cancer research , stat3 , stat protein , breast cancer , biology , tumor progression , interleukin 6 , cytokine , medicine , cancer , signal transduction , immunology , microbiology and biotechnology
Ductal carcinoma in situ (DCIS) is a nonobligate precursor to invasive breast cancer. Only a small percentage of DCIS cases are predicted to progress; however, there is no method to determine which DCIS lesions will remain innocuous from those that will become invasive disease. Therefore, DCIS is treated aggressively creating a current state of overdiagnosis and overtreatment. There is a critical need to identify functional determinants of progression of DCIS to invasive ductal carcinoma (IDC). Interrogating biopsies from five patients with contiguous DCIS and IDC lesions, we have shown that expression of the long noncoding RNA BHLHE40‐AS1 increases with disease progression. BHLHE40‐AS1 expression supports DCIS cell proliferation, motility, and invasive potential. Mechanistically, BHLHE40‐AS1 modulates interleukin (IL)‐6/signal transducer and activator of transcription 3 (STAT3) activity and a proinflammatory cytokine signature, in part through interaction with interleukin enhancer‐binding factor 3. These data suggest that BHLHE40‐AS1 supports early breast cancer progression by engaging STAT3 signaling, creating an immune‐permissive microenvironment.